02 May 2003 : Original article
Peroxynitrite-PARP-1 pathway in traumatic brain injury in rats
V. Besson, N. Croci, R. Boulu, M. Plotkine, C. Marchand-VerrecchiaMed Sci Monit 2003; 9(1): 3-0 :: ID: 14988
Abstract
Background:Nitric oxide and free radicals contribute to injury elicited by traumatic brain injury (TBI) [1,2]. Peroxynitrite, resulting from the combination of nitric oxide and superoxide anion triggers DNA strand breakage, leading to the activation of poly(ADP-ribose)polymerase-1 (PARP-1) [3]. As excessive activation of this enzyme induces cell death, we examine the implication of peroxynitrite-PARP-1 pathway in the post-traumatic outcomes of focal TBI caused by fluid percussion on rats [4]. Material/Methods:In a first experiment, animals were killed 30 min, 2, 4, 6, 24, 48 and 72h after TBI for immunohistochemistry of a) 3-nitrotyrosine as a footprint of peroxynitrite production and b) poly(ADP-ribose) as a marker of PARP-1 activation. In a second experiment, the effect of 3-aminobenzamide (3-AB), a widely used PARP inhibitor, was investigated on the neurological deficit, the cerebral lesion and the activation of PARP-1. Rats were given 3-AB (10 and 30 mg/kg, i.p.) or its vehicle 30 min before, and 24, 48 and 72h after TBI. Results: Immunohistochemistry showed that 3-nitrotyrosine and poly(ADP-ribose) were present as early as 30 min post-injury, and persisted for 72h. Treatment with 3-AB significantly decreased the neurological deficit, the cerebral lesion and the poly(ADP-ribose) staining induced by TBI. Conclusions: The present study indicates that TBI induces peroxynitrite production associated with PARP-1 activation. Treatment with 3-AB, a PARP inhibitor, decreases the neurological deficit, the cerebral lesion and the PARP-1 activation caused by TBI. Thus, PARP-1 is involved in the pathogenesis of TBI and may be a promising therapeutic target for the treatment of brain trauma.References: 1.Mésenge C et al: J Neurotrauma, 1996; 13: 209-214 2.Mésenge C et al: J Pineal Res, 1998; 25: 41-46 3.Virág L, Szabó C: Pharmacol Rev, 2002; 54: 375-429 4.Toulmond S et al: Brain Res, 1993; 620: 24-31
Keywords: 3-nitrotyrosine, 3-aminobenzamide, neuroprotection, poly(ADP-ribose)polymerase-1, peroxynitrite, traumatic brain injury
323 0
Editorial
01 June 2023 : Editorial
Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic PreparednessDOI: 10.12659/MSM.941209
Med Sci Monit 2023; 29:e941209
In Press
01 Jun 2023 : Clinical Research
Root Canal Numbers and Configurations in 1080 Permanent Canine Teeth in 270 Saudi Subjects Using Cone-Beam ...Med Sci Monit In Press; DOI: 10.12659/MSM.940472
01 Jun 2023 : Clinical Research
Internal Orifice Alloy Closure: A New Procedure for Treatment of Perianal Fistulizing Crohn’s DiseaseMed Sci Monit In Press; DOI: 10.12659/MSM.940873
01 Jun 2023 : Clinical Research
Effectiveness of Needle Aspiration versus Surgical Excision for Symptomatic Synovial Cysts of the Hip: A Si...Med Sci Monit In Press; DOI: 10.12659/MSM.940187
01 Jun 2023 : Clinical Research
Influence of Insulin Resistance on Diabetes NephropathyMed Sci Monit In Press; DOI: 10.12659/MSM.939482
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952